Table 5.
Consistency characteristics of guidelines
| Guidelines | N | Mean (SD) | ||
|---|---|---|---|---|
| C1* | C2* | C3* | ||
| NICE | 74 | 6.93 (0.34) | 6.96 (0.26) | 6.96 (0.26) |
| NZGG | 38 | 6.55 (0.76) | 6.39 (0.82) | 6.53 (0.65) |
| SIGN | 18 | 5.78 (1.11) | 6.00 (0.91) | 4.67 (0.59) |
| ADA | 17 | 1.00 (0.00) | 2.65 (1.17) | 3.18 (1.24) |
| FIGO | 40 | 1.20 (0.72) | 1.83 (1.65) | 3.45 (2.33) |
| Endocrine Society | 25 | 5.04 (1.72) | 6.68 (1.25) | 5.88 (1.81) |
| CDA | 17 | 3.53 (2.43) | 4.18 (2.40) | 3.88 (1.69) |
| API | 22 | 5.45 (2.22) | 5.45 (2.22) | 5.04 (2.38) |
| IDF | 13 | 1.00 (0.00) | 3.38 (2.29) | 2.77 (1.24) |
| Queensland | 8 | 1.75 (0.71) | 3.88 (1.36) | 3.13 (1.25) |
| HKCOG | 13 | 1.00 (0.00) | 1.23 (0.60) | 1.15 (0.55) |
| A.N.D. | 15 | 6.00 (0.00) | 5.67 (0.49) | 5.93 (0.26) |
| DDG | 21 | 1.05 (0.22) | 1.43 (0.75) | 2.24 (1.30) |
| CMA | 40 | 1.00 (0.00) | 1.30 (0.72) | 1.15 (0.48) |
| Total | 361 | 4.00 (2.74) | 4.43 (2.59) | 4.49 (2.42) |
C1*: consistency between search strategy and selection of evidence
C2*: consistency between selected evidence and interpretation
C3*: consistency between interpretation and resulting recommendations